Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results

[1]  M. Buti,et al.  96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. , 2018, Journal of hepatology.

[2]  S. Chen,et al.  Interpretation of liver stiffness measurement‐based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2‐year prospective study , 2018, Journal of viral hepatitis.

[3]  M. Buti,et al.  Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma , 2017, Digestive Diseases and Sciences.

[4]  John F. Flaherty,et al.  No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment , 2017, Journal of viral hepatitis.

[5]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[6]  C. Trautwein,et al.  Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany , 2016, Digestive Diseases and Sciences.

[7]  P. Marcellin,et al.  Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France , 2016, Digestive Diseases and Sciences.

[8]  M. Buti,et al.  Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml) , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[9]  S. Chen,et al.  Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial , 2015, Journal of viral hepatitis.

[10]  M. Buti,et al.  Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.

[11]  John F. Flaherty,et al.  Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. , 2014, Journal of hepatology.

[12]  M. N. Kim,et al.  Long‐term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[13]  P. Marcellin,et al.  Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load , 2013, Hepatology.

[14]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[15]  R. Gish,et al.  Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  J. Pawlotsky,et al.  Liver stiffness diminishes with antiviral response in chronic hepatitis C , 2011, Alimentary pharmacology & therapeutics.

[17]  Vincent Wai-Sun Wong,et al.  Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.

[18]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.